The KEAP1/NFE2L2 mutations were observed in many common malignant tumors, including lung adenocarcinoma 11,12,19,21, which might define a molecular subset of rapidly progressing tumor 57. This evidence concerns the gene NFE2L2 and lung adenocarcinoma.